Table A2.21Number of treatment cycles

First line (cycle length)Number of cyclesStandard deviationDistribution
FOLFOX (2 weeks)8.991.73Gamma (mean, SD)
FOLFIRI (2 weeks)7.890.71Gamma (mean, SD)
XELOX (3 weeks)5.870.78Gamma (mean, SD)
XELIRI (3 weeks)6.502 (assumption)Uniform
Second line (cycle length)Number of cyclesStandard deviationDistribution
FOLFOX (2 weeks)7.132 (assumption)Uniform
FOLFIRI (2 weeks)6.002 (assumption)Uniform
XELOX (3 weeks)5.002 (assumption)Uniform
XELIRI (3 weeks)5.532 (assumption)Uniform
irinotecan (3 weeks)5.212 (assumption)Uniform

From: Appendix 2, Mixed treatment comparison and cost-effectiveness analysis for sequences of oxaliplatin and irinotecan-based chemotherapy in the treatment of advanced and metastatic colorectal cancer

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.